
NASDAQHealthcareMedical - Devices
أحدث البيانات المتاحة
0.2297 US$
−0.0117 US$ · -4.85%
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
الإغلاق السابق
0.2297 US$
−0.0117 US$ · -4.85%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
نطاق اليوم
السعر الحالي 0.2297 US$
نطاق 52 أسبوعًا
السعر الحالي 0.2297 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
70
أقل من القيمة
المشاعر
46
مختلط
المخاطر
75
مخاطر مرتفعة
الزخم
17
هبوط قوي
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
نطاق اليوم
السعر الحالي 0.2297 US$
نطاق 52 أسبوعًا
السعر الحالي 0.2297 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2026 | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 |
|---|---|---|---|---|---|
| الإيرادات | 401.95 مليون USD | 458.51 مليون USD | 446.55 مليون USD | 447.61 مليون USD | 429.91 مليون USD |
| تكلفة البضاعة المباعة | 290.49 مليون USD | 311.54 مليون USD | 303.63 مليون USD | 293.65 مليون USD | 269.95 مليون USD |
| الربح الإجمالي | 111.45 مليون USD | 146.97 مليون USD | 142.92 مليون USD | 153.96 مليون USD | 159.96 مليون USD |
| البحث والتطوير | 37.75 مليون USD | 47.94 مليون USD | 49.73 مليون USD | 57.13 مليون USD | 57.75 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 83.97 مليون USD | 91.19 مليون USD | 92.69 مليون USD | 94.45 مليون USD | 94.06 مليون USD |
| نفقات التشغيل | 137.9 مليون USD | 139.13 مليون USD | 142.42 مليون USD | 151.58 مليون USD | 151.81 مليون USD |
| دخل الفوائد | — | 1.19 مليون USD | — | — | — |
| مصاريف الفوائد | 35.31 مليون USD | 12.95 مليون USD | 11.62 مليون USD | 10.63 مليون USD | 8.13 مليون USD |
| الاستهلاك والإطفاء | 7.94 مليون USD | 6.15 مليون USD | 5.91 مليون USD | 4.53 مليون USD | 5.51 مليون USD |
| الدخل التشغيلي | −26.44 مليون USD | 7.84 مليون USD | 504 ألف USD | 2.38 مليون USD | 8.15 مليون USD |
| صافي الدخل | −49.19 مليون USD | −1.59 مليون USD | −15.55 مليون USD | −9.28 مليون USD | −5.35 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI821.21 ألف0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
Fidelity Enhanced Small Cap ETFFESM346.09 ألف0.01%6.41 مليار USD0.28%45.46 US$+0.46%
Vanguard Extended Market ETFVXF312.99 ألف0.00%95.4 مليار USD0.05%235 US$+0.80%
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM28.41 ألف0.00%693.75 مليون USD0.89%57.70 US$+0.92%
Invesco RAFI US 1500 Small-Mid ETFPRFZ26.49 ألف0.00%2.67 مليار USD0.36%53.16 US$+0.64%
Vanguard Morningstar Total Stock Market ETFVTI
Fidelity Enhanced Small Cap ETFFESM
Vanguard Extended Market ETFVXF
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM
Invesco RAFI US 1500 Small-Mid ETFPRFZالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.